Objective The aim of this study was to assess the cost effectiveness of the novel fixed-dose anticoagulant rivaroxaban compared with the current standard of care, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF). Methods A Markov model was constructed to model the costs and health outcomes of both treatments, potential adverse events, and resulting health states over 35 years. Analyses were based on a hypothetical cohort of 65-yearold patients with non-valvular AF at moderate to high risk of stroke. The main outcome measure was cost per qualityadjusted life-year (QALY) gained over the lifetime, and was assessed from the German Statutory Health Insurance (SHI) perspective. Costs and utility data were drawn from public data and the literature, while event probabilities were derived from both the literature and rivaroxaban's pivotal ROCKET AF trial. Results Stroke prophylaxis with rivaroxaban offers health improvements over warfarin treatment at additional cost. From the SHI perspective, at baseline the incremental costeffectiveness ratio of rivaroxaban was €15,207 per QALY gained in 2014. The results were robust to changes in the majority of variables; however, they were sensitive to the price of rivaroxaban, the hazard ratios for stroke and intracranial hemorrhage, the time horizon, and the discount rate. Conclusions Our results showed that the substantially higher medication costs of rivaroxaban were offset by mitigating the shortcomings of warfarin, most notably frequent dose regulation and bleeding risk. Future health economic studies on novel oral anticoagulants should evaluate the cost effectiveness for secondary stroke prevention and, as clinical data from direct head-to-head comparisons become available, new anticoagulation therapies should be compared against each other.
and mortality [1] . It leads to a fivefold increase in the risk of ischemic stroke, and accounts for 15 % of strokes in all age groups and 30 % in persons older than 80 years [2] . In western countries, AF occurs in 0.5-1 % of the general population, particularly among the elderly. In Germany, the prevalence of AF is 4-6 % in individuals above the age of 60 years, and 9-16 % in those aged 80 years and above [3] [4] [5] . Due to the expected increase in life expectancy and the prevalence of risk factors (i.e. arterial hypertension, heart failure, and obesity), the prevalence of AF is expected to double within the next 50 years [3] .
Because of the increased risk of ischemic stroke, a primary aim in the management of AF is to prevent thromboembolic events using antithrombotic therapy. While the annual risk of stroke in patients with AF without antithrombotic therapy is 4.5 % [6] , several randomized controlled trials (RCTs) confirmed that anticoagulation with vitamin K antagonists such as warfarin reduces the risk of stroke in non-valvular AF by up to 64 % [7] . However, the efficacy of warfarin therapy may be impaired by several food and drug interactions, delayed onset of action, or metabolic diversity. In addition, it requires frequent laboratory monitoring of the international normalized ratio (INR)-a measure of the clotting tendency of blood [8, 9] . Since over-anticoagulation is associated with severe or fatal hemorrhages, one main target of AF management is to keep the probability of hemorrhages as low as possible [10, 11] .
Rivaroxaban is a direct factor Xa inhibitor with predictable pharmacokinetic and pharmacodynamic properties and a wide therapeutic margin [12] . In a double-blind RCT (ROCKET AF) that included 14,264 patients with nonvalvular AF who were at increased risk of stroke, rivaroxaban was shown to be non-inferior to warfarin for the prevention of stroke or systemic embolism [13] . There were no significant between-group differences in the risk of major bleeding, and intracranial and fatal bleeding occurred even less frequently in the rivaroxaban group, with a hazard ratio (HR) of 0.67 (95 % CI 0.47-0.93) [13] . In addition to these clinical advantages, the application of rivaroxaban does not require INR monitoring or frequent dose adjustments [13] .
With daily medication costs of €3.27 (warfarin €0.23) [14] , the prescription of rivaroxaban for the prevention of stroke and other diseases (e.g. prophylaxis of deep vein thrombosis after knee or hip replacement surgery) achieved a total of 25.5 million doses in Germany in 2012 compared with 0.7 million doses in the previous year, which can be attributed to the indication expansion for stroke prevention in AF [15] . Because the costs of this new rivaroxaban regimen exceed the costs of the former warfarin regimen, decision makers are increasingly interested in analyses that evaluate the monetary consequences, particularly in relation to clinical effects.
Several studies have evaluated the cost effectiveness of rivaroxaban for stroke prevention in non-valvular AF from a healthcare payer perspective. Whereas European studies yielded an incremental cost-effectiveness ratio (ICER) ranging from dominance to €20,089 per quality-adjusted life-year (QALY) [16] [17] [18] [19] [20] , the ICERs of studies conducted in the US or Canada ranged from $3,200 to $55,800 per QALY [21] [22] [23] . However, to date, no study has evaluated the cost effectiveness of rivaroxaban compared with conventional warfarin for the German healthcare system. Due to budget constraints for the German Statutory Health Insurance (SHI), additional payments for preventing stroke should result in a reduction of morbidity and/or mortality. Therefore, the aim of this analysis was to compare projected quality-adjusted survival, costs, and cost effectiveness of adjusted-dose warfarin and rivaroxaban for stroke prevention in patients with non-valvular AF from a German SHI perspective.
Methods
A cost-effectiveness analysis was performed for patients aged 65 years with non-valvular AF and without contraindications to anticoagulation who were at moderate to high risk of stroke. The Markov model [24] compared two treatment strategies for the prevention of stroke in patients with non-valvular AF-fixed-dose rivaroxaban (20 mg daily) and adjusted-dose warfarin with a target INR of 2.0-3.0.
Because our model was literature-based, several searches in MEDLINE, EMBASE and the Cochrane library aimed at identifying current input data for modeling (i.e. clinical efficacy, utilities, and costs) that were appropriate to reflect the German healthcare system. For data on clinical efficacy, we searched for both single RCTs and metaanalyses that compared rivaroxaban with warfarin in nonvalvular AF. One of the criteria for consideration was a high level of accordance between the study population and our model population. For data on quality of life, the terms 'quality of life' and 'QALY' were combined with the keywords 'atrial fibrillation', 'stroke', 'hemorrhage', 'bleeding', 'prevention', 'prophylaxis', 'warfarin' or 'rivaroxaban'. We assessed the quality and relevance of all data, as well as the potential for bias. The clinical data obtained were assumed to be appropriate if (i) the study population was similar to our model population, and (ii) data were of high methodological quality according to The Cochrane Collaboration's tool for assessing risk of bias in randomized trials (i.e. we assessed random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting). Data on costs were considered to be acceptable if they reflected the German cost structure and if bias was unlikely (i.e. appropriate methods for identification, quantification, and prizing of resources). Data on utility should be based on preference ratings from patients with AF obtained either with the timetradeoff or standard gamble methods.
The literature search revealed that the ROCKET AF trial was well in accordance with our model population. ROCKET AF was a pivotal, multicenter, randomized, double-blind, event-driven trial that compared rivaroxaban and warfarin in a head-to-head comparison at 1,178 participating sites in 45 countries [13] .
In our analysis, patients who received warfarin were assumed to maintain a level of INR control consistent with that observed in ROCKET AF (mean, 55 % time in the therapeutic range) [13] . These values were lower than those observed in routine practice in Germany (67 %) [25] . According to the ROCKET AF trial, the increased risk of stroke was indicated by a history of stroke, transient ischemic attack (TIA), systemic embolism, or at least two of the following risk factors: heart failure or a left ventricular ejection fraction B35 %, hypertension, age C75 -years, or the presence of diabetes mellitus (i.e. a CHADS 2 score of 2 or more on a scale ranging from 1 to 6, with higher scores indicating a greater risk for stroke) [26] .
Decision Model
The health states in the model were in accordance with the relevant outcomes stated in the European guidelines for the management of AF [27] , and comprised 'healthy with AF'; 'ischemic stroke'; 'intracranial hemorrhage (ICH)'; 'major extracranial hemorrhage (major ECH)', i.e. a clinically overt bleeding associated with fatal or disabling outcome or involvement of a critical anatomic site; 'clinically relevant non-major bleeding', i.e. an overt bleeding not meeting the criteria for major bleeding but requiring medical intervention (see 'Outcome Definitions' in the electronic supplementary Appendix); 'recurrent or combined events'; and 'death' (Fig. 1) . Following the recommendations in a review on economic analyses for the treatment of stroke [28] , 'ischemic stroke' and 'ICH' were assumed to be associated with fatal, major disabling, minor disabling, or reversible outcomes (i.e. TIA lasting less than 24 h) [for details see 'Outcome Definitions' in the electronic supplementary Appendix]. Because of the increased frequency of permanent disabling outcomes after an ischemic stroke or ICH, a time horizon of 35 years with monthly cycles was chosen, starting at 65 years of age.
Health benefits (in terms of QALYs) and costs were assigned to each health state. Both costs and benefits were discounted at an annual rate of 3 % [29] . The probabilities of adverse events were derived from the ROCKET AF trial unless stated otherwise. Results were expressed in terms of incremental quality-adjusted life expectancy, incremental net costs (over 35 years or until death), and ICERs. All costs were expressed in 2014 Euros. Analyses were performed using the TreeAge Pro Suite 2011 (TreeAge Software, Williamstown, MA, USA) and Microsoft Excel 2011 (Microsoft Corporation, Redmond, WA, USA).
To validate the model, debugging was conducted and model assumptions were scrutinized, i.e. the technical accuracy of the model was checked for input data entry and potential programming errors. Adjustments were made to the model if the simulated results deviated from these data sources. For internal validation, we compared the survival curves with 95 % confidence intervals between the Markov model and the Kaplan-Meier method, based on the original clinical data. In addition, we underwent a comparison of outputs with inputs. For external validation, we conducted a comparison of model-based results with that of other cohorts. Furthermore, we assessed the extent to which other models for stroke prevention with rivaroxaban came to different conclusions, and explained potential sources of these differences (cross-validation). 
Probabilities of Adverse Outcomes
The relative treatment effect and the patients' adherence were assumed to remain constant for the duration of antithrombotic therapy [30] . The probabilities of death were adjusted for age. Data on the underlying background mortality (i.e. without stroke and hemorrhage) were obtained from German public databases [31] and increased either for the presence of AF alone (HR 1.2) [32] or AF in conjunction with stroke history (HR 3.7) [33] . As the risk for stroke and ICH increases with age, multiplicative adjustment was used to increase the annual probabilities of stroke and ICH, applying HRs of 1.4 per decade for stroke [34] and 1.97 per decade for ICH [35] (monthly compounded) [ Table 1 ].
Stroke and Hemorrhage Severity
To consider different degrees of functional deficits, initial ischemic strokes or ICHs were classified into four categories according to their severity-fatal, major disability, minor disability or no disability (reversible, TIA lasting less than 24 h). The proportions of fatal, disabling and nondisabling ischemic strokes were derived from ROCKET AF [13] . As costs and utilities differ significantly between major and minor disabilities [36] , disabling ischemic strokes were further classified into major and minor disabling strokes [10] . Similarly, reflecting severity of neurologic deficit, ICHs were classified in accordance with the four categories listed above [37] (detailed in Table 1 ).
To consider combined and recurrent events of ischemic stroke and ICH, patients who developed a second minor ischemic stroke were assumed to pass over to the major stroke health state, and patients with a second major ischemic stroke were assumed to die [38, 39] . Equivalent transitions were assumed for minor and major ICH [40, 41] . Patients with a history of ischemic stroke or ICH were assumed to die in the case of any further disabling stroke or ICH.
Quality-of-Life Estimates
For the utility of warfarin treatment without complications, there was only one preference rating from patients with AF, which was based on the time-tradeoff method [42] . Because of the lack of data on reduced quality-of-life when taking rivaroxaban once daily, the utility was assumed to be equivalent to values on aspirin treatment [42] . Similar to rivaroxaban, aspirin is a once-daily, orally-taken drug with standard dosing, similar side effects and without regular INR controls [42] .
The utilities of stroke and ICH were derived from a meta-analysis on quality-of-life estimates for stroke [43] . The utility of both 'major ECH' and 'clinically relevant non-major bleeding' were derived from patient ratings on major bleedings [44] . Because patients in these health states usually recover in a short period of time, they were assigned a short-term disutility lasting 1 month for major ECH and 2 days for clinically relevant non-major bleeding [45, 46] .
Costs
According to the SHI perspective, the analysis considered direct costs only, i.e. costs referring to the consumption of resources resulting from the provision of healthcare interventions and directly attributable to these. Because of a lack of data on resource consumption unrelated to AF, medical costs not associated with antithrombotic treatments, ischemic strokes or hemorrhagic events were not included. Costs were expressed in 2014 Euros.
Drug Treatment Costs
Drug costs for each treatment option were defined according to 'Rote Liste', a list of pharmaceuticals in Germany (including EU registrations and specific medical products) [14] . While rivaroxaban is administered in a once-daily fixed dose (20 mg), warfarin requires dose adjustment according to the results of INR testing [47] . For this analysis, costs were calculated for a dose of warfarin 5 mg/day [47] . The costs of monitoring of INR for warfarin were assumed to accrue weekly for the first 9 weeks of therapy and every 4 weeks thereafter (i.e. 13 INR tests per year) [47] . The costs of INR testing were based on the Uniform Value Scale for outpatient services within the SHI scheme in 2012 [48] .
Costs of Adverse Events
Costs of adverse events were separated into one-time costs and monthly costs. All details on cost data and values used for modeling are listed in Table 1 , and details on resource utilization are provided in Tables 1 and 2 of the electronic  supplementary Appendix. Long-term costs (i.e. monthly costs) mainly depended on the degree of functional deficits due to stroke or ICH. Whereas monthly costs of disabling stroke (minor or major) and ICH (resulting in minor or major disability) were derived from the literature [49, 50] , patients in the state 'stroke and ICH' were assumed to have a cost increase of 27 % compared with those having a major disabling ICH without a stroke [49, 50] . After hospitalization, approximately 53 % of patients with ischemic stroke were referred to outpatient rehabilitation centres, while 45 % received inpatient rehabilitation. In approximately 23 % of patients, long-term care in a nursing home was necessary (55 % received outpatient nursing-care services). Resource use of outpatient care after ischemic stroke is provided in Table 2 of the electronic supplementary Appendix [50] . When discharged from hospital, 22.6 % of patients with ICH went home or went to a nursing home, 32.4 % were referred to another acute hospital, and 20.4 % went to an inpatient rehabilitation clinic [49] .
Estimates of one-time costs of treatment for disabling ischemic neurologic events and ICHs were derived from a German cost-of-illness study that used a bottom-up approach [49] . This study stratified one-time costs based on the severity of disability rated on the Barthel Index (BI). According to these categories, the costs of minor disability were based on patients with a BI C95, and the costs of major disabling outcomes were based on patients with a BI B90. Intubation/decompressive surgery was assumed to be performed in 16.2 %/5.6 % of patients with ICH and in 1.5 %/3.4 % of those with ischemic stroke. Overall, 72.1 % of all patients underwent physiotherapy, 30.9 % underwent speech therapy, and 30.1 % underwent occupational therapy [49] .
These estimates for one-time costs of ischemic stroke and ICHs were confirmed by two recent German studies [51, 52] . Furthermore, because one of these studies indicated that the costs of acute hospitalization differed significantly between patients with and without AF, the cost estimates of both minor and major disabling strokes and ICHs were increased by 23 % due to the presence of AF [51] .
Because outcomes of ischemic stroke and ICH without disability were assumed to incur one-time costs only, these were assumed to be equal to the acute treatment costs of a TIA (which results in neurologic dysfunction lasting less than 24 h) [52] . Similarly, both major ECH and clinically relevant non-major bleeding were assumed to cause onetime costs only. For the costs relating to major ECH, we considered inpatient costs of gastrointestinal bleeding [53] (the most frequent major extracranial bleeding form in ROCKET AF [13] ). In contrast, for the costs of a clinically relevant non-major bleeding we assumed treatment in an outpatient setting. Therefore, only costs of outpatient services were calculated [48] . 
Sensitivity Analyses
One-way sensitivity analyses were performed for all variables incorporated in the decision model by using 95 % confidence intervals of the means unless stated otherwise (Table 1) . While most variables used for sensitivity analysis were classified according to the 95 % confidence intervals obtained from the ROCKET AF [13] or the literature, drug costs were classified according to prices for a minimum drug packaging size and statutory discounts (16 % for rivaroxaban and 10 % for warfarin) [54] . In addition, the dosage of warfarin depends on the results from INR testing with dose modifications between 5 and 20 %, and the cost range for INR testing depends on the number of performed laboratory tests (i.e. up to six additional tests per year were allowed for this analysis) [47] . Adherence rates varied to 90 % and 80 % for both rivaroxaban and warfarin treatment.
Additionally, probabilistic sensitivity analysis was performed using second-order Monte Carlo simulation [55] with 10,000 iterations. Simulation of outcomes was conducted by randomly sampling distributions of all variables (through replacement). For this purpose, normal distribution was applied to all clinical event rates, beta distribution for utilities, as well as probabilities and gamma distribution for resource use and costs. Furthermore, a Dirichlet distribution was used for subcategories (severities) of stroke and ICH, accounting for its mutually exclusive character (for detailed parameters see Table 1 ).
Results

Base-Case Analysis
Quality-adjusted life expectancy in patients with non-valvular AF receiving rivaroxaban amounted to 11.06 QALYs, while those treated with adjusted-dose warfarin amounted to 10.35 QALYs. The corresponding total costs were €9,464 for warfarin and €20,238 for rivaroxaban. Thus, the ICER for rivaroxaban compared with warfarin was €15,207 per QALY.
Sensitivity Analyses
In deterministic sensitivity analyses, the cost effectiveness of rivaroxaban versus warfarin was robust (i.e. ICERs varied by less than €2,000 per QALY) to changes in the majority of model variables, including variations in underlying clinical event rates, costs, utilities and discount rates.
Varying the daily drug costs of rivaroxaban, the ICER remained below €20,000 per QALY gained. Similarly, the ICER of rivaroxaban compared with warfarin was below €20,000 per additional QALY over the full range of HRs for ischemic stroke, and did not exceed €25,000 per QALY gained for varying the HR of ICH. Furthermore, the ICER of rivaroxaban was slightly sensitive to changes in the baseline risk of ischemic stroke (i.e. a CHADS 2 score of 2-6), and became more favorable with increasing baseline risk of stroke in patients taking warfarin (Table 2) .
Varying the HRs of both ischemic stroke and ICH confirmed the robustness of the ICER (detailed results depicted in Fig. 2) . Time in the therapeutic range, reflecting the level of INR control (target INR of 2.0-3.0), affects the treatment efficacy of warfarin and the HRs for ischemic stroke and ICH (i.e. increasingly favoring warfarin, with more time spent in the therapeutic range) [56, 57] . Furthermore, varying adherence rates to 90 % and 80 % for both warfarin and rivaroxaban treatment yielded ICERs below €20,000 per QALY.
Varying the patients' age at the initiation of antithrombotic treatment to between 65 and 100 years, rivaroxaban was cost effective at a willingness to pay (WTP) of €25,000 per QALY for all ages. In contrast, the results were highly sensitive for the chosen time horizon, with more favorable ICERs if the time horizon was extended. A threshold analysis showed that an ICER of €25,000 is reached at a time horizon of between 10 and 11 years (Fig. 3) . In addition, the results were moderately sensitive to changes in the discount rate of future costs and QALYs, with increasing ICERs for higher discount rates.
In the probabilistic sensitivity analysis, rivaroxaban was shown to be cost effective in 73 % of the iterations at a CI confidence interval, ECH extracranial hemorrhage, ICER incremental cost-effectiveness ratio, ICH intracranial hemorrhage, p.a. per annum, QALY quality-adjusted life-year a Results shown for variables which varied the ICER by more than €2,000 per QALY WTP of €15,000, and in 99 % using a WTP of €25,000 per QALY (Fig. 4) .
Discussion
This cost-effectiveness analysis suggests that, in Germany, treatment with rivaroxaban compared with warfarin yielded 0.71 additional QALY at incremental costs of €10,775. In the base-case model, initiation of antithrombotic treatment resulted in an ICER below €25,000 per QALY, even for the oldest patients, confirming results from earlier cost-effectiveness analysis [58] . The results were shown to be robust in deterministic and probabilistic sensitivity analyses. The gain in QALYs resulted mainly from a significant decrease in the rate of ICH events. Compared with warfarin, this result showed a substantial decrease of treatment costs for ICH and an increase of QALYs attributable to the avoidance of associated long-term disability and mortality. In Germany, as in many countries, cost-utility analyses based on QALYs are not accepted by decision makers and clinicians due to concerns regarding solidarity, equity and fairness [59] . However, in certain contexts for health economic evaluations the QALY can be used as an overall measure of benefit [59] . Moreover, if an additional benefit for a drug is proven, the SHI negotiates with the pharmaceutical company concerning a supplement on top of the price of the expedient comparative therapy [60] . In such negotiations, cost-utility analyses can be an additional argument to achieve the price a company aims at. Fig. 2 Two-way sensitivity analysis for the HR of ischemic stroke and ICH. This graph illustrates a two-way sensitivity analysis varying the HRs of ischemic stroke and ICH together, using a willingness to pay of €25,000 per QALY. HR hazard ratio, ICH intracranial hemorrhage, QALY qualityadjusted life-year Compared with some recent cost-effectiveness analyses that evaluated anticoagulants for stroke prevention, our analysis differed in the choice of data regarding utility. In contrast to our study, previous cost-effectiveness analyses of dabigatran [61] , apixaban [62] , and rivaroxaban [21] were based on a physician survey by O'Brien and Gage [45] which rated the utility of ximelagatran treatment. However, ximelagatran might result in liver function abnormalities requiring frequent liver function monitoring [45] , an adverse event not associated with rivaroxaban. Therefore, to avoid underestimation of utility in patients treated with rivaroxaban, for this analysis, as in Lip et al. [63] , a quality-of-life estimate for treatment with aspirin was chosen as it matches the oral once-daily mode of administration and the standard dosing without regular INR controls in patients with AF [42] .
To compare the results of our study with those of previously published analyses, there are important methodological differences, particularly with regard to the costeffectiveness study on rivaroxaban [21] . In that study, Lee et al. used probabilities for clinical events and distributions for outcomes of adverse events that differ from those specified in ROCKET AF. In addition, in the analysis of Lee et al. the higher baseline rate of stroke in patients receiving warfarin was based on patients at high risk of stroke with a CHADS 2 score of 3 [21] . According to ROCKET AF, our analysis included patients at moderate to high risk of stroke, as indicated by a CHADS 2 score of 2 or more. Another methodological difference affecting qualityadjusted survival and incremental QALYs is that Lee et al. used uniform distributions for ischemic stroke outcomes and fatality rates after major ECH, whereas in our analysis outcome distributions were applied that were in accordance with the administered therapy. If the treatment a patient had received was not considered, this might have resulted in an underestimation of the effectiveness of rivaroxaban.
The most notable difference between our analysis and previously published studies is accounted for by the cost structure. For example, substantially higher total costs quantified by Lee et al. [21] were a result of drug costs that were notably higher for either treatment option (i.e. the daily medication costs were 2.7-fold higher for warfarin and 1.6-fold higher for rivaroxaban) [21] . In addition to these differences in drug costs, the long-term costs of disabling strokes or ICHs were three-to eightfold higher in the analysis of Lee et al. These cost discrepancies are in line with an international study of medical costs of atherothrombotic disease in European countries, which found a tenfold difference in costs for ischemic stroke, with 18-75 % of this difference attributable to long-term costs [64] .
Despite methodological differences, our findings are in line with those from previously published analyses, confirming the cost effectiveness of new oral anticoagulants in different settings [65] . In fact, in several studies, dabigatran etexilate was found to be cost effective among different countries and settings [61, [66] [67] [68] [69] . Similarly, two analyses recently established the cost effectiveness of rivaroxaban [21, 22] from a US payer/Medicare perspective. Moreover, the study by Harrington et al. [22] analysed the ICERs of all three new oral anticoagulants recently approved for stroke prevention in AF, which suggests rivaroxaban as the most cost-effective alternative (each compared with warfarin). On the contrary, a Canadian study that evaluated the cost effectiveness of these three new anticoagulants versus warfarin, showed that rivaroxaban is dominated by dabigatran (150 mg) and apixaban treatment [23] . Note that some of the studies are based on indirect comparisons, which are known to yield inconsistent results [63] . Based   Fig. 4 Cost-effectiveness acceptability curves for different thresholds of willingness to pay. QALY quality-adjusted life-year on an indirect comparison of rivaroxaban versus dabigatran, it appears that rivaroxaban is less effective than dabigatran 150 mg but more effective than dabigatran 110 mg, with cohorts significantly differing in terms of CHADS 2 score and stroke history [70] . This might, to some degree, explain the differences in the results.
Furthermore, several studies have evaluated the cost effectiveness of rivaroxaban in a European setting. Although there were substantial differences in the model structure and usage of utilities, their results are similar to those of our analysis (ICER ranging from dominance to €20,089 per QALY) [16] [17] [18] [19] [20] .
Limitations
The results of our analysis may be affected by important limitations. First, data on efficacy and adverse events used for the analysis were predominantly derived from ROCKET AF [13] . Efficacy observed in RCTs may be considerably lower in clinical practice (e.g. higher INR control observed in routine practice in Germany-67 % [25] compared with 55 % in Rocket AF-may increase the HRs and lower the efficacy of rivaroxaban) as clinical studies generally enroll healthier patients, monitor patients more intensively and achieve higher levels of adherence [71] . Results from a recent study on rivaroxaban in daily care in Germany indicate that major bleeding rates and the associated mortality rates may be lower in real life [72] . However, these rates are comprised of the 95 % confidence intervals observed in Rocket AF [13] .
A second limitation results from the usage of ROCKET AF data and its trial duration (median follow-up duration of 1.9 years). By assuming efficacy and patient adherence to be constant for the duration of antithrombotic therapy by extrapolation, a potential increase of clinical events beyond this follow-up would increase the ICER of rivaroxaban. As adherence contributes to anticoagulation control [73] , it was varied in our analyses. We would expect that higher adherence to warfarin therapy increases the percentage of time spent in the therapeutic range (target INR of 2.0-3.0) and modifies the ICER towards favoring warfarin as it was proven that high levels of INR control reduced the frequency of stroke, as well as the associated severity and mortality [10] . New warfarin dosing systems, such as computerized assistance, may improve treatment quality, although prescribing significantly more frequent INR testing [74] . Due to a lack of data, medical costs unrelated to antithrombotic treatments, ischemic strokes or hemorrhagic events were not included. Similarly, there was a lack of clinical data specified for the German population since ROCKET AF was a multinational trial.
Third, estimates for one-time costs of treatment for disabling ischemic neurologic events and ICHs were derived from a German cost-of-illness study which shows similar results to two recent German studies [50, 51] . However, in these studies, costs were not stratified according to the severity of the resulting disability, and long-term costs were not stated.
Finally, certain limitations of the underlying model structure should be considered. Unlike similar analyses, in our model patients experiencing any major bleeding could neither discontinue rivaroxaban or warfarin therapy nor change to aspirin. Although these treatment changes have been justified by a previously published decision analysis on the anticoagulation of AF patients with ICHs [75] , they are not in line with European guidelines for stroke prevention in AF. According to these guidelines, the use of antiplatelet therapy (e.g. aspirin) should be limited to the few patients who refuse any form of oral anticoagulation [27] .
Additionally, the present model did not include a health state for patients suffering a myocardial infarction, which may affect event rates and the costs of the analysis.
To keep the model structure manageable, stroke severity did not account for prior ischemic stroke, even though it was found to be an independent predictor [10] .
Conclusions
The present cost-effectiveness analysis suggests rivaroxaban as a cost-effective treatment alternative to adjusteddose warfarin for patients with non-valvular AF at moderate to high risk for stroke. The substantially higher medication costs of rivaroxaban were offset by mitigating the shortcomings of warfarin, most notably regular INR monitoring with frequent dose adjustments and bleeding risk. As a result, treatment with rivaroxaban was found to be more effective than warfarin treatment, with an ICER of €15,207 per QALY gained favoring rivaroxaban.
Future health economic studies on novel oral anticoagulants in patients with AF should evaluate the cost effectiveness of rivaroxaban for secondary stroke prevention and, as clinical data from direct head-to-head comparisons become available, new anticoagulation therapies should be compared against each other. In addition, costs for patients and caregivers, as well as indirect costs, might be included, thus considering a societal perspective. Furthermore, clinical trials should include thorough stroke and bleeding risk assessments using the CHA 2 DS 2 -VASc [76] and HAS-BLED [77] score, as recommended by most guidelines [27] , enabling more detailed subgroup analysis.
